The latest stroke data from the pandemic illuminates patterns
But like the real world, the reports come with many uncertainties
More actionable alterations detected in myeloid malignancies versus cytogenetics
More experienced viral suppression versus traditional clinic visits
More than one-third of patients achieved major pathologic response with nivolumab-ipilimumab.
Large proportion of intermediate- to high-risk patients could avoid aggressive therapy
Co-existence tied to severe disease, organ failure, and longer hospital stays
No significant difference in days without delirium or coma
ASCO guideline covers patient selection, treatment options, follow-up
Major response rate of 21%, encouraging survival with single-agent atezolizumab